| Literature DB >> 36014583 |
Maria Khan1, Zahid Manzoor2, Muhammad Rafiq1, Shaukat Hussain Munawar2, Muhammad Yasir Waqas1, Hamid Majeed3, Syed Zahid Ali Shah4, Riaz Hussain4, Hafiz Iftikhar Hussain5, Tehreem Tahir6, Katarzyna Kotwica-Mojzych7, Mariusz Mojzych8.
Abstract
The plant Caralluma edulis is traditionally used against diabetes and inflammatory conditions in Pakistan. This study was designed to provide scientific validation of the traditional use of Caralluma edulis. Phytochemicals were extracted from the plant by different solvents (distilled water, methanol, ethanol, and acetone) using the Soxhlet's extraction method. Bioactive compounds were detected by gas chromatography-mass spectrometry (GC-MS). The in vitro anti-inflammatory activities (albumin denaturation, membrane stabilization, and proteinase inhibition) and antioxidant capacity (DPPH scavenging activity, FRAP reducing activity) of different extracts from Caralluma edulis were assessed. The antidiabetic potential of Caralluma edulis plant extracts was determined in acute and subacute diabetic rabbit models. Oxidative stress and enzymatic antioxidant status were also estimated in MDA, CAT, and SOD levels. Results showed that the methanol extract yielded the highest contents of phenolics, flavonoids, alkaloids, and terpenoids. The in vitro anti-inflammatory activity and antioxidant potential of the methanol extract were the highest among the tested solvents. The tested extracts did not show any remarkable antidiabetic activity in the acute diabetic model. However, all tested extracts demonstrated antidiabetic potential in the subacute diabetic model. No adverse effect was observed at the tested dose (200 mg/kg) of Caralluma edulis extracts in experimental animals. It is concluded that methanol is the key solvent for extracting bioactive compounds from Caralluma edulis. The plant can be used against inflammatory disorders and may prove a potential candidate for drug development. Long-term use of Caralluma edulis at the tested dose (200 mg/kg) showed antidiabetic properties in the animal model.Entities:
Keywords: Caralluma edulis; GC-MS analysis; anti-inflammatory; antidiabetic; antioxidant; phytochemical screening; rabbits
Mesh:
Substances:
Year: 2022 PMID: 36014583 PMCID: PMC9412639 DOI: 10.3390/molecules27165346
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1GC-MS chromatogram of methanolic extract of Caralluma edulis plant.
Phytoconstituents in the methanol extract of Caralluma edulis plant as detected by GC-MS analysis.
| S. No | RT in min | Name of the Compound | Molecular Formula | Peak Area % |
|---|---|---|---|---|
| 1 | 5.279 | Propane, 1,2,3,-trimethoxy- | C6H14O3 | 0.91 |
| 2 | 5.279 | 2-Oxoacetic acid, ethyl ester, oxime | C4H7NO3 | 0.91 |
| 3 | 7.376 | ( | C14H12 | 0.94 |
| 4 | 7.376 | 2,3,5,6-Tetrafluoroanisole | C7H4F4O | 0.94 |
| 5 | 7.376 | Butyric acid, 4-amino-3-(4-methoxyphenyl)- | C13H19NO3 | 0.94 |
| 6 | 10.206 | C16H32O2 | 2.09 | |
| 7 | 10.206 | Pentadecanoic acid | C15H30O2 | 2.09 |
| 8 | 10.206 | Octadecanoic acid | C18H36O2 | 2.09 |
| 9 | 11.302 | 9,12-Octadecadienoic acid ( | C18H32O2 | 0.91 |
| 10 | 11.333 | C18H34O2 | 1.52 | |
| 11 | 11.333 | C18H34O2 | 1.52 | |
| 12 | 11.333 | C18H34O2 | 1.52 | |
| 13 | 13.655 | Bis(2-ethylhexyl) phthalate | C24H38O4 | 1.03 |
| 14 | 13.655 | Phthalic acid, cyclohexyl 2-pentyl ester | C19H26O4 | 1.03 |
| 15 | 13.881 | Heptadecane | C17H36 | 0.59 |
| 16 | 14.379 | Heptacosane, 1-chloro- | C27H55Cl | 0.84 |
| 17 | 14.856 | Tetracosane | C24H50 | 0.93 |
| 18 | 16.203 | Hentriacontane | C31H64 | 17.63 |
| 19 | 16.203 | Triacontane | C30H62 | 17.63 |
| 20 | 16.827 | Octadecamethyloctasiloxane | C18H54O7Si8 | 2.88 |
| 21 | 16.827 | 1,1,3,3,5,5,7,7,9,9,11,11,13,13-Tetradecamethylheptasiloxane | C14H42O6Si7 | 2.88 |
| 22 | 16.827 | 1 | C15H13N | 2.88 |
| 23 | 16.916 | Benzo[ | C15H13N | 1.92 |
| 24 | 16.916 | Cyclotrisiloxane, hexamethyl- | C6H18O3Si3 | 1.92 |
| 25 | 17.057 | Tetracosane | C24H50 | 49.63 |
| 26 | 17.057 | 1-Iodohexadecane | C16H33I | 49.63 |
| 27 | 17.057 | Octadecane | C18H38 | 49.63 |
| 28 | 17.341 | gamma-sitosterol | C29H50O | 4.12 |
| 29 | 17.341 | beta-sitosterol | C29H50O | 4.12 |
| 30 | 17.807 | 1-Benzazirene-1-carboxylic acid, 2,2,5a-trimethyl-1a-[3-oxo-1-butenyl] perhydro-, methyl ester | C15H23NO3 | 2.37 |
| 31 | 17.807 | 9,10-Methanoanthracen-11-ol,9,10-dihydro-9,10,11-trimethyl- | C18H18O | 2.37 |
| 32 | 18.048 | Eicosane | C20H42 | 5.63 |
Figure 2Extraction yield of Caralluma edulis using different solvents. All values are the mean ± SD (n = 3). Means of a column with different letters significantly differ by Tukey’s test at p < 0.01.
Effect of different solvents on phenolic, flavonoid, and alkaloid content of Caralluma edulis.
| Extraction Solvent | Phenolics | Flavonoids | Alkaloids | Terpenoids (%, g/g) |
|---|---|---|---|---|
| Distilled water | 6.20 ± 0.99 b | 0.63 ± 0.11 c | 0.14 ± 0.01 d | 0.45 ± 0.05 c |
| Methanol | 14.3 ± 1.95 a | 1.88 ± 0.18 a | 1.44 ± 0.22 a | 1.22 ± 0.09 a |
| Ethanol | 4.44 ± 0.60 bc | 0.62 ± 0.13 c | 1.32 ± 0.17 ab | 0.97 ± 0.14 ab |
| Acetone | 2.91± 0.75 c | 0.76 ± 0.12 bc | 0.88 ± 0.19 bc | 0.52 ± 0.07 c |
All values are the mean ± SD (n = 3). Means within a column with different letters significantly differ by Tukey’s test at p < 0.05.
Phytochemicals’ concentration of different extracts from Caralluma edulis measured by spectrophotometer.
| Name of Compound | Wavelength | Pharmacological | ||||
|---|---|---|---|---|---|---|
| Campesterol | 254 nm | Antioxidant, anti-inflammatory, antidiabetic | 0.309 | 0.205 | 0.368 | 0.265 |
| β-sitosterol (Phytosterol) | 210 nm | Antioxidant, anti-inflammatory, antidiabetic | 0.159 | 0.324 | 0.279 | 1.239 |
| ( | 285 nm | Antioxidant, hepatoprotective, anti-inflammatory | 0.347 | 0.651 | 0.418 | 0.517 |
| Gallic acid | 256 nm | Radical scavenging, anti-inflammatory, immunoregulatory | 0.884 | 1.341 | 0.947 | 0.748 |
| Pentadecanoic acid | 364 nm | Antidiabetic | 0.336 | 0.427 | 0.254 | 0.387 |
Figure 3The 50% inhibitory concentration (IC50) values of DPPH scavenging activity of different Caralluma edulis extracts. All values are the mean ± SD (n = 3). Means of a column with different letters significantly differ by Tukey’s test at p < 0.05.
FRAP assay activity and IC50 values of different extracts from Caralluma edulis plant.
| Extraction Solvent | FRAP (μmol Fe (II)/g DW) | IC50 (μg/mL) |
|---|---|---|
| Distilled water | 256.3 ± 8.54 d | 369.2 ± 9.11 d |
| Methanol | 543.8 ± 7.68 a | 175.5 ± 3.67 a |
| Ethanol | 429.4 ± 9.12 b | 230.6 ± 4.68 b |
| Acetone | 376.1± 6.97 c | 282.7 ± 5.53 c |
All values are the mean ± SD (n = 3). Means within a column with different letters significantly differ by Tukey’s test at p < 0.05.
In vitro anti-inflammatory activity of different Caralluma edulis extracts.
| Samples | IC50 Values (µg/mL) | ||
|---|---|---|---|
| Albumin | Proteinase | Membrane | |
| Water extract | 759.0 ± 19.9 a | 589.9 ± 22.5 a | 835.1 ± 21.7 a |
| Methanolic extract | 26.1 ± 2.25 c | 408.4 ± 15.3 c | 319.3 ± 13.6 cd |
| Ethanolic extract | 36.0 ± 4.33 c | 421.0 ± 12.6 c | 355.8 ± 18.7 c |
| Acetone extract | 94.3 ± 6.97 b | 576.3 ± 17.2 ab | 586.4 ± 19.1 b |
| Inhibitory activity, % | |||
| Aspirin (100 µg/mL) | 32.4 ± 5.4 | 35.6 ± 2.3 | 28.2 ± 1.9 |
All values are the mean ± SD (n = 3). Means within a column with different letters significantly differ by Tukey’s test at p < 0.05.
Acute effect of Caralluma edulis extracts on blood glucose levels in alloxan-induced diabetic rabbits.
| Group | Dose (mg/kg) | Mean Blood Glucose Concentration + S.D. (mg/dL) | |||
|---|---|---|---|---|---|
| 0 h | 1 h | 3 h | 6 h | ||
| Control (healthy) | 10 | 117 ± 7.02 | 128 ± 5.03 | 126 ± 2.08 | 117 ± 4.16 |
| Glibenclamide | 5 | 121 ± 9.50 | 106 ± 4.16 * | 92 ± 5.27 ** | 82 ± 8.93 ** |
| 200 | 114 ± 5.29 | 124 ± 6.50 | 114 ± 9.01 | 109 ± 3.05 | |
| 200 | 109 ± 7.09 | 119 ± 7.02 | 115 ± 3.51 | 104 ± 2.43 | |
| 200 | 118 ± 7.02 | 111 ± 11.06 | 118 ± 3.67 | 107 ± 3.46 | |
| 200 | 115 ± 6.52 | 112 ± 1.70 | 117 ± 2.56 | 108 ± 3.65 | |
* p < 0.05 significant from the control animals, ** p < 0.01 significant from the control animals.
Acute effect of Caralluma edulis extracts on serum insulin levels in alloxan-induced diabetic rabbits.
| Group | Dose (mg/kg) | Mean Serum Insulin Level + S.D. (µIU/dL) | |||
|---|---|---|---|---|---|
| 0 h | 1 h | 3 h | 6 h | ||
| Control (healthy) | 10 | 11.66 ± 1.65 | 12.17 ± 1.20 | 13.2 ± 0.60 | 12.41 ± 0.56 |
| Glibenclamide | 5 | 12.46 ± 2.54 | 14.58 ± 0.85 * | 16.31 ± 0.95 ** | 18.53 ± 0.71 ** |
| 200 | 11.76 ± 1.30 | 13.13 ± 0.38 | 14.50 ± 0.65 | 12.05 ± 0.48 | |
| 200 | 11.50 ± 0.79 | 13.66 ± 0.56 | 14.62 ± 0.60 | 14.1 ± 0.50 | |
| 200 | 11.93 ± 1.50 | 13.18 ± 0.94 | 14.70 ± 0.55 | 12.40 ± 0.45 | |
| 200 | 11.56 ± 0.96 | 13.12 ± 0.62 | 14.49 ± 0.54 | 12.3 ± 0.36 | |
* p < 0.05 significant from the control animals, ** p < 0.01 significant from the control animals.
Subacute effect of Caralluma edulis extracts on blood glucose levels in alloxan-induced diabetic rabbits.
| Group | Dose (mg/kg) | Mean Blood Glucose Concentration + S.D. (mg/dL) | |||
|---|---|---|---|---|---|
| 1st Day | 3rd Day | 5th Day | 8th Day | ||
| Control (healthy) | 10 | 121.6 ± 8.14 | 113.1 ± 7.54 | 118.3 ± 7.09 | 110.6 ± 7.05 |
| Diabetic control (a) | 10 | 427.9 ± 12.01 *** | 451.5 ± 12.01 *** | 428.4 ± 8.50 *** | 374.6 ± 4.04 *** |
| Glibenclamide (b) | 5 | 399.7 ± 9.60 * | 388.8 ± 11.06 ** | 379.6 ± 9.49 ** | 342.6 ± 7.37 ** |
| 200 | 406.2 ± 8.54 | 414.2 ± 6.02 * | 400.1 ± 9.01 * | 356.2 ± 3.60 * | |
| 200 | 401.8 ± 6.02 * | 394.3 ± 15.01 ** | 390.2 ± 8.86 ** | 346.6 ± 5.85 ** | |
| 200 | 410.1 ± 10.59 | 419.6 ± 10.5 * | 399.6 ± 6.35 * | 357.1 ± 3.60 * | |
| 200 | 419.6 ± 6.80 | 417.2 ± 7.02 * | 402.3 ± 10.01 * | 358.3 ± 6.80 * | |
* p < 0.05 significant from the control animals, ** p < 0.01 significant from the control animals, *** p < 0.001 significant from the control animals, (a) compared to vehicle control, (b) compared to diabetic control.
Subacute effect of Caralluma edulis extracts on serum insulin levels in alloxan-induced diabetic rabbits.
| Group | Dose (mg/kg) | Mean Serum Insulin Level + S.D. (µIU/dL) | |||
|---|---|---|---|---|---|
| 1st Day | 3rd Day | 5th Day | 8th Day | ||
| Control (healthy) | 10 | 13.48 ± 0.46 | 13.25 ± 0.40 | 13.70 ± 0.14 | 14.16 ± 0.19 |
| Diabetic control (a) | 10 | 5.95 ± 0.04 *** | 5.70 ± 0.12 *** | 5.83 ± 0.15 ** | 6.03 ± 0.71 *** |
| Glibenclamide (b) | 5 | 6.13 ± 0.08 * | 6.17 ± 0.09 ** | 6.22 ± 0.05 ** | 6.48 ± 0.26 ** |
| 200 | 6.08 ± 0.23 | 6.01 ± 0.28 * | 6.12 ± 0.13 * | 6.27 ± 0.38 * | |
| 200 | 6.12 ± 0.05 * | 6.15 ± 0.07 ** | 6.18 ± 0.11 ** | 6.43 ± 0.15 ** | |
| 200 | 6.01 ± 0.09 | 5.98 ± 0.12 * | 6.13 ± 0.21 * | 6.25 ± 0.22 * | |
| 200 | 6.04 ± 0.17 | 5.97 ± 0.15 * | 6.12 ± 0.17 * | 6.23 ± 0.13 * | |
* p < 0.05 significant from the control animals, ** p < 0.01 significant from the control animals, *** p < 0.001 significant from the control animals, (a) compared to vehicle control, (b) compared to diabetic control.
Malondialdehyde (MDA), superoxide dismutase (SOD) and catalase levels in serum of alloxan-induced diabetic rabbits after treated with Caralluma edulis extracts.
| Group | Dose (mg/kg) | Mean Serum SOD (U/mL), MDA (nmol/mL) and Catalase Levels (kU/I) + S.D. | |||
|---|---|---|---|---|---|
|
| 10 |
|
|
|
|
| SOD | 87.8 ± 7.53 | 86.4 ± 8.56 | 88.6 ± 7.76 | 87.6 ± 1.85 | |
| MDA | 4.43 ± 0.47 | 4.33 ± 0.08 | 4.63 ± 0.12 | 4.71 ± 0.17 | |
| Catalase | 54.2 ± 2.54 | 58.0 ± 1.47 | 59.7 ± 1.10 | 55.2 ± 1.15 | |
|
| |||||
| SOD | 53.5 ± 6.75 *** | 55.4 ± 5.06 *** | 60.3 ± 7.05 *** | 60.4 ± 1.95 *** | |
| MDA | 9.17 ± 0.16 *** | 9.31 ± 0.14 *** | 9.39 ± 0.14 *** | 9.75 ± 0.16 *** | |
| Catalase | 31.7 ± 0.66 *** | 32.8 ± 1.51 *** | 34.6 ± 0.75 *** | 39.2 ± 0.26 *** | |
|
| 5 | ||||
| SOD | 58.1 ± 5.27 | 63.4 ± 9.09 | 76.1 ± 2.51 ** | 72.9 ± 3.09 ** | |
| MDA | 8.72 ± 0.06 | 8.84 ± 0.15 | 8.58 ± 0.17 ** | 7.77 ± 0.18 ** | |
| Catalase | 29.2 ± 1.68 | 34.9 ± 1.07 | 39.0 ± 0.72 ** | 48.0 ± 1.41 ** | |
|
| 200 | ||||
| SOD | 55.1 ± 6.51 | 57.9 ± 7.60 | 72.1 ± 2.98 * | 69.7 ± 0.75 ** | |
| MDA | 8.89 ± 0.23 | 8.88 ± 0.21 | 8.83 ± 0.15 * | 8.47 ± 0.18 ** | |
| Catalase | 30.6 ± 1.05 | 31.5 ± 1.05 | 37.0 ± 1.25 * | 41.4 ± 0.37 * | |
|
| 200 | ||||
| SOD | 58.6 ± 5.93 | 61.5 ± 8.12 | 75.8 ± 1.51 ** | 71.4 ± 1.15 ** | |
| MDA | 8.77 ± 0.12 | 8.84 ± 0.18 | 8.65 ± 0.12 ** | 7.86 ± 0.20 ** | |
| Catalase | 28.8 ± 0.70 | 33.0 ± 1.20 | 38.1 ± 0.55 ** | 47.7 ± 0.43 ** | |
|
| 200 | ||||
| SOD | 59.4 ± 6.70 | 60.5 ± 8.55 | 70.7 ± 1.71 * | 69.4 ± 1.09 ** | |
| MDA | 8.78 ± 0.20 | 8.87 ± 014 | 7.78 ± 0.14 * | 8.62 ± 0.27 ** | |
| Catalase | 29.4 ± 0.88 | 30.1 ± 0.57 | 37.1 ± 1.66 * | 42.4 ± 0.66 * | |
|
| 200 | ||||
| SOD | 57.9 ± 7.40 | 58.6 ± 6.57 | 71.9 ± 1.62 * | 70.4 ± 1.05 ** | |
| MDA | 8.76 ± 0.22 | 8.84 ± 0.19 | 8.80 ± 0.25 * | 8.50 ± 0.28 ** | |
| Catalase | 29.1 ± 1.56 | 30.9 ± 0.43 | 37.0 ± 0.40 * | 41.9 ± 0.52 * | |
* p < 0.05 significant from the control animals, ** p < 0.01 significant from the control animals, *** p < 0.001 significant from the control animals, (a) Compared to vehicle control, (b) Compared to diabetic control.
Subacute effect of Caralluma edulis extracts on body weights in alloxan-induced diabetic rabbits.
| Group | Dose (mg/kg) | Mean Body Weight + S.D. (kg) Percent Increase from the Initial Weight | |||
|---|---|---|---|---|---|
| 1st Day | 3rd Day | 5th Day | 8th Day | ||
| Control (healthy) | 10 | 2.19 ± 0.5 | 2.26 ± 0.4 (3.1%) | 2.3 ± 0.3 (5.3%) | 2.32 ± 0.6 (9.3%) |
| Diabetic control (a) | 10 | 2.40 ± 0.8 | 2.43 ± 0.3 (3.8%) | 2.47 ± 0.6 (4.4%) | 2.52 ± 0.7 (7.6%) |
| Glibenclamide (b) | 5 | 2.73 ± 0.7 | 2.77 ± 0.6 (2.9%) | 2.84 ± 0.2 (4.6%) | 2.91 ± 0.5 (8.1%) |
| 200 | 2.58 ± 0.6 | 2.63 ± 0.8 (3.1%) | 2.67 ± 0.8 (5.1%) | 2.73 ± 0.4 (7.0%) | |
| 200 | 2.79 ± 0.7 | 2.86 ± 0.9 (2.3%) | 2.92 ± 0.7 (6.4%) | 2.95 ± 0.8 (8.1%) | |
| 200 | 2.29 ± 0.5 | 2.32 ± 0.2 (3.3%) | 2.41 ± 0.3 (7.5%) | 2.49 ± 0.9 (9.5%) | |
| 200 | 2.35 ± 0.4 | 2.38 ± 0.3 (3.4%) | 2.47 ± 0.5 (6.9%) | 2.53 ± 0.8 (8.3%) | |
(a) Compared to vehicle control, (b) compared to diabetic control.
Figure 4Photographs of the liver tissues from different groups (20×, H&E): (a) control; (b) Glibenclamide (5 mg/kg) reference drug groups; (c) Caralluma edulis water extract (200 mg/kg); (d) Caralluma edulis methanol extract (200 mg/kg); (e) Caralluma edulis ethanol extract (200 mg/kg); (f) Caralluma edulis acetone extract (200 mg/kg).